Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17233398 | 0.96 | CYP3A4 (0.38) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL17233382 | 0.96 | CYP3A4 (0.38) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL27801743 | 0.82 | — | — | |
| SCHEMBL4760493 | 0.79 | — | — | |
| SCHEMBL28389114 | 0.77 | — | — | |
| SCHEMBL7204674 | 0.77 | CASP2 (0.52) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL12829898 | 0.77 | CASP2 (0.46) | TSHRCYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL5049817 | 0.75 | FAAH (0.47) | TSHRALDH1A1MAPTHSD17B10L3MBTL1 | |
| SCHEMBL4167987 | 0.75 | — | — | |
| SCHEMBL2257886 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181305-B2 | Exendin-4 peptide analogues | SANOFI (FR) | 2015-11-10 | — | — | US | claimed |
| US-8697647-B2 | Hybrid polypeptides with selectable properties | ASTRAZENECA PHARMACEUTICALS LP | 2014-04-15 | — | — | US | claimed |
| US-20120253023-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | claimed |
| US-6335320-B1 | Method of treating fibrotic conditions | UCB S.A. (BE) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253023-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | IAPP, IGFBP1, PGF | TSHR 808/4885CYP3A4 4838/4885CYP2D6 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.